Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 104 | 0.74 |
| pathways Reactome | 3 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 3500
Sealed predictions
- VAC14 in dopamine neurons, braak+0.23 (p 0.545) → -0.69 (p 0.039)receipt 3507
Swarm cases
receipt 3507: VAC14 in dopamine neurons, braak
- power
- full sample -0.36 (p 0.142, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.36 (p 0.142, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.40 (p 0.101, n 18). could be the mix.
- skeptic
- leave-one-out range -0.45 to -0.27, sign flips 0; without severely affected donors -0.36 (p 0.142, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.68 (p 0.0021, n 18) vs -0.36 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VAC14 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up VAC14 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.30 p 0.286 (needs p < 5.2e-4)
Receipts
loading the receipts